Danaher 2011 Annual Report Download - page 14

Table of Contents

The table below provides the unfulfilled orders attributable to each of our five segments at the end of 2011 and 2010 ($ in millions):

  
Test & Measurement $715 $ 641
Environmental 378 382
Life Sciences & Diagnostics 455 186
Dental 64 71
Industrial Technologies 555 534
Businesses contributed to the Apex joint venture — —
Total $2,167 $1,814
We expect that a large majority of the unfilled orders as of December 31, 2011 will be delivered to customers within 3 to 4 months of such date. Given the
relatively short delivery periods and rapid inventory turnover that are characteristic of most of our products and the shortening of product life cycles, we
believe that backlog is indicative of short-term revenue performance but not necessarily a reliable indicator of medium or long-term revenue performance.

At December 31, 2011, we employed approximately 59,000 persons, of whom approximately 26,000 were employed in the United States and approximately
33,000 were employed outside of the United States. Of our United States employees, approximately 1,500 were hourly-rated, unionized employees. Outside the
United States, we have government-mandated collective bargaining arrangements and union contracts in certain countries, particularly in Europe where many
of our employees are represented by unions and/or works councils. For a discussion of risks related to employee relations, please refer to “Item 1A. Risk
Factors.”

The table below describes our research and development expenditures over each of the last three years, by segment and in the aggregate ($ in millions):

   
Test & Measurement $312 $258 $216
Environmental 153 136 116
Life Sciences & Diagnostics 341 193 117
Dental 78 73 52
Industrial Technologies 135 111 93
Businesses contributed to the Apex joint venture — 3 6
Total $1,019 $774 $600
We conduct research and development activities for the purpose of developing new products, enhancing the functionality, effectiveness, ease of use and
reliability of our existing products and expanding the applications for which uses of our products are appropriate. Our research and development efforts
include internal initiatives and those that use licensed or acquired technology. The Company conducts research and development activities on a business-by-
business basis, primarily in North America, Europe and Asia. We anticipate that we will continue to make significant expenditures for research and
development as we seek to provide a continuing flow of innovative products to maintain and improve our competitive position. For a discussion of the risks
related to the need to develop and commercialize new products and product enhancements, please refer to “Item 1A. Risk Factors.” Customer-sponsored
research and development was not significant in 2011, 2010 or 2009.

Although the substantial majority of our revenue in 2011 was from customers other than governmental entities, each of our segments has agreements relating to
the sale of products to government entities. As a result, we are subject to various statutes and regulations that apply to companies doing business with
governments. For a discussion of risks related to government contracting requirements, please refer to “Item 1A. Risk Factors.”
12
Source: DANAHER CORP /DE/, 10-K, February 24, 2012 Powered by Morningstar® Document Research℠
The information contained herein may not be copied, adapted or distributed and is not warranted to be accurate, complete or timely. The user assumes all risks for any damages or losses arising from any use of this information,
except to the extent such damages or losses cannot be limited or excluded by applicable law. Past financial performance is no guarantee of future results.